CN1733125A - Effective parts of Immature Bitter Orange or trifoliate-orange root-bark or their effective parts composition and preparation method and pharmaceutical purpose thereof - Google Patents
Effective parts of Immature Bitter Orange or trifoliate-orange root-bark or their effective parts composition and preparation method and pharmaceutical purpose thereof Download PDFInfo
- Publication number
- CN1733125A CN1733125A CN 200410070123 CN200410070123A CN1733125A CN 1733125 A CN1733125 A CN 1733125A CN 200410070123 CN200410070123 CN 200410070123 CN 200410070123 A CN200410070123 A CN 200410070123A CN 1733125 A CN1733125 A CN 1733125A
- Authority
- CN
- China
- Prior art keywords
- fructus aurantii
- effective site
- immaturus
- preparation
- aurantii immaturus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses the effective parts of immature butter orange or trifoliate-orange root-bark or their effective parts composition and preparation method and pharmaceutical purpose, which are extracted with ethanol and water, and can be used for antiphlogistic and cough-relieving. The invention also discloses the pharmaceutical composition using these effective parts as the active constituents, which can be made into various forms including granules, tablets, capsules, drop pills, soft extracts, and liquids.
Description
Technical field
The present invention relates to the field of Chinese medicines.Particularly, relate to Fructus Aurantii Immaturus or Fructus Aurantii effective site or its compositions, the invention still further relates to the preparation method of this effective site, the present invention also relates to this effective site and promote the purposes of gastric motility medicine, lack the medicinal usage of respiratory tract infection diseases such as disease and tracheitis, cough specifically at gastric motilitys such as treatment or prevention flatulence, anorexia, dyspepsias in preparation.
Background technology
Fructus Aurantii Immaturus (Fructus aurantii immaturus) is the dry young fruit of rutaceae Citrus aurantium Linn. Citrus aurantiumL. and mutation or Fructus Citri sinensis Citrus sinensis Osbeck.Have the dispelling the stagnated QI removing food stagnancy, the diffusing painful abdominal mass of reducing phlegm, the stagnate effect of relieving distension of regulating the flow of QI to ease the stomach, row.
Fructus Aurantii (Fructus aurantii) is the dry immature fruit of rutaceae Citrus aurantium Linn. Citrus aurantium L. and variety thereof, has regulating the flow of QI to ease the stomach, the effect of the stagnant relieving distension of row.
Fructus Aurantii Immaturus, Fructus Aurantii are conventional Chinese medicine, are applied to the existing two thousand years of the history of curing the disease clinically, are widely used in the traditional Chinese medical science compound preparation of curing the disease.Once had pharmacological evaluation to show, the Fructus Aurantii Immaturus medicament can make the laboratory animal gastrointestinal smooth muscle shrink the rhythm and pace of moving things to be increased, but Shang Weijian promotes the report of digestive tract power active ingredient or active ingredient and preparation thereof to Fructus Aurantii Immaturus, Fructus Aurantii.
In order to determine the effective ingredient or the effective site of Fructus Aurantii Immaturus, we have adopted the targeting under the active guidance to follow the trail of separation method and have studied, and each separated part is carried out active testing.Experimental result shows, isolated Hesperidin (Hesperidin), naringin (Naringin) and the effective site and the compositions thereof that contain these two kinds of compositions all have the effect that promotes digestive tract power from Fructus Aurantii Immaturus.
Wherein the structure of Hesperidin is:
Molecular formula: C
28H
34O
15, thin dendroid acicular crystal (pH6～7 precipitation gained).M.p.258～262 ℃, [α]
D 20-76 ° (c 2, pyridine).Slightly be slightly soluble in methanol and hot glacial acetic acid, be dissolved in acetone, benzene and chloroform hardly, and be soluble in diluted alkaline and pyridine.
The structure of naringin is:
Molecular formula: C
27H
32O
14, being dried to weight at 110 ℃ is two water things, m.p.171 ℃.[α]
D 19-82 ° (ethanol).1 gram is dissolved in 1000ml water, is dissolved in acetone, ethanol, hot acetic acid and hot water, is insoluble to ether, hexane and chloroform.
Summary of the invention
The object of the present invention is to provide a kind of Fructus Aurantii Immaturus or Fructus Aurantii effective site.
Another object of the present invention is to provide the compositions that contains this effective site.
Another purpose of the present invention is to provide the preparation method of this effective site.
Another object of the present invention is to provide this effective site to promote the purposes of digestive tract power medicine in preparation.
Another purpose of the present invention is to provide this effective site to lack the medicinal usage of respiratory tract infection diseases such as disease and tracheitis, cough at gastric motilitys such as treatment or prevention flatulence, anorexia, dyspepsias.
Fructus Aurantii Immaturus of the present invention or Fructus Aurantii effective site are to make with following preparation method:
With Chinese medicine Fructus Aurantii Immaturus or Fructus Aurantii, pulverize, use ethanol extraction, merge extractive liquid, reclaims ethanol to there not being the alcohol flavor, obtains the effective site of Fructus Aurantii Immaturus or Fructus Aurantii.Preferred effective site contains Hesperidin and the naringin more than 20%.
Fructus Aurantii Immaturus of the present invention or Fructus Aurantii effective site or compositions are mixed by recipe quantity with adjuvant, granulate, can be made into dosage forms such as tablet, capsule, be used for the treatment of disease and acute and chronic respiratory tract diseases such as flatulence, dyspepsia, infantile anorexia.
Below example is confirmed such use by experiment.
1. animal acute toxicity test
(1) oral administration
Healthy male mice, body weight 18-25 gram is used Fructus Aurantii Immaturus effective site or compositions (Hesperidin and naringin ratio are 1: 1) to be made into aqueous solution respectively and is irritated stomach 5.0g/kg, in a continuous week, does not see dead mouse.
(2) drug administration by injection
Healthy male mice, body weight 18-25 gram is used Fructus Aurantii Immaturus effective site or compositions (Hesperidin and naringin ratio are 1: 1) to be made into aqueous solution respectively and is carried out lumbar injection, in a continuous week, observes the dead mouse situation.The LD of Fructus Aurantii Immaturus effective site
50Value is the LD of 4.80 ± 0.550g/kg, compositions
50Value is 4.10 ± 0.410g/kg.
2. to the influence of mice gastric emptying
Adopt atropine, dopamine inhibition mice gastric emptying and neostigmine to cause the mouse small intestine carbon powder and advance two kinds of experimental models, Fructus Aurantii Immaturus effective site and compositions promote the effect of digestive tract power among checking the present invention.
The experimental drug thing is respectively among the present invention gained Fructus Aurantii Immaturus effective site and compositions among the embodiment, faces with preceding and prepares with 0.5%CMC-Na; Reference substance is motilium (an Xi'an Janssen Pharmaceutica lot number 010203), faces with preceding and prepares with distilled water.
2.1 atropine, dopamine are suppressed the influence of mice gastric emptying
Fructus Aurantii Immaturus and Fructus Aurantii effective site and compositions and blank group relatively have significant difference (P＜0.001) among the present invention.The results are shown in Table 1 and table 2.
Table 1 Fructus Aurantii Immaturus and Fructus Aurantii effective site and compositions suppress the influence of gastric emptying motion to atropine
| Group | Dosage (g/kg) | Number of animals (only) | Residual rate in the methyl orange stomach (X ± S) |
| Blank group Fructus Aurantii Immaturus effective site Fructus Aurantii active component composition motilium | -- 1.0 1.0 1.0 0.048 | 12 12 12 12 12 | 371.82±116.02 242.69±88.08 241.60±86.05 231.32±80.34 191.98±54.68 |
Table 2 Fructus Aurantii Immaturus and Fructus Aurantii effective site and compositions suppress the influence of gastric emptying motion to dopamine
| Group | Dosage (g/kg) | Number of animals (only) | Residual rate in the stomach (X ± S) |
| Blank group Fructus Aurantii Immaturus effective site Fructus Aurantii active component composition motilium | -- 1.0 1.0 1.0 0.048 | 12 12 12 12 12 | 45.09±5.96 33.26±6.79 32.75±6.21 31.47±5.38 39.59±3.93 |
2.2 neostigmine is caused the propulsive influence of mouse small intestine carbon powder
Fructus Aurantii Immaturus and Fructus Aurantii effective site and compositions and blank group relatively have significant difference (P＜0.01) among the present invention, the results are shown in Table 3.
Table 3 Fructus Aurantii Immaturus and Fructus Aurantii effective site and compositions cause mice gastric emptying and the propulsive influence of small intestinal carbon powder to neostigmine
| Group | Dosage (g/kg) | Number of animals (only) | Residual rate in the stomach (X ± S) | Carbon powder propelling rate (X ± S) |
| Blank group Fructus Aurantii Immaturus effective site Fructus Aurantii effective site | -- 1.0 1.0 | 10 10 10 | 22.58±5.28 16.11±5.39 15.89±5.12 | 59.07±16.39 79.31±16.81 78.92±15.92 |
| The compositions motilium | 1.0 0.048 | 10 10 | 15.74±3.73 15.26±3.16 | 78.42±13.61 79.15±9.29 |
From above result of study, can draw the present invention and have following characteristics:
1. the present invention has carried out new excavation to Chinese medicine Fructus Aurantii Immaturus and Fructus Aurantii, has found Fructus Aurantii Immaturus and Fructus Aurantii effective site and the compositions new purposes in pharmacy.
2. Fructus Aurantii Immaturus among the present invention and Fructus Aurantii effective site and compositions toxicity are little, and pharmacological action is strong, have good prospect in medicine.
3. raw material of substance Fructus Aurantii Immaturus among the present invention and Fructus Aurantii resource are extensive, inexpensive, and preparation technology is simple.
4. effective site of Fructus Aurantii Immaturus or Fructus Aurantii or compositions can adopt the conventional method of this area to be prepared into various dosage forms, as tablet, pill, capsule, granule, injection etc. with pharmaceutically acceptable excipient among the present invention.The preferred dosage form that contains the effective-part medicinal composition of Fructus Aurantii Immaturus of the present invention or Fructus Aurantii is an oral formulations.Dosage be 20-500mg/ people/time, every day 1-3 time.
Various details embodiment, but content of the present invention is not limited to this fully.
The specific embodiment
Embodiment 1: Fructus Aurantii Immaturus fine powder 600g, 4 times (crude drug: the weight of solvent ratio is 1: 6 with 95% ethanol extraction; 1: 4; 1: 4; 1: 4), merge extractive liquid, reclaims ethanol to there not being the alcohol flavor, adds distilled water to 600ml, and water liquid is used petroleum ether, ethyl acetate, n-butanol extraction 6 times successively, each 200ml.After concentrating, the n-butanol extraction position gets 90g, last D101 type macroporous resin column, water, 25% ethanol, 50% ethanol, 95% ethanol elution successively, 50% ethanol elution position is through containing Hesperidin and the mixed total glycosides (55g) of naringin more than 20% behind the concentrate drying.
Embodiment 2: Fructus Aurantii fine powder 600g, 3 times (crude drug: the weight of solvent ratio is 1: 8 with 70% ethanol extraction; 1: 6; 1: 6), merge extractive liquid, reclaims ethanol to there not being the alcohol flavor, adds distilled water to 600ml, and water liquid is used petroleum ether, ethyl acetate, n-butanol extraction 4 times successively, each 300ml.The n-butanol extraction position behind concentrate drying 82g, last D101 type macroporous resin column, water, 25% ethanol, 50% ethanol, 95% ethanol elution successively, 50% ethanol elution position is through Hesperidin and naringin (47g) that must be more than 20% behind the concentrate drying.
Claims (7)
1, Fructus Aurantii Immaturus or Fructus Aurantii effective site can obtain with following preparation method: with Chinese medicine Fructus Aurantii Immaturus or Fructus Aurantii, pulverize, use ethanol extraction, merge extractive liquid, reclaims ethanol to there not being the alcohol flavor, obtain the effective site of Fructus Aurantii Immaturus or Fructus Aurantii, contain Hesperidin and naringin more than 20%.
2, according to described Fructus Aurantii Immaturus of claim 1 or Fructus Aurantii effective site, the ratio of its contained Hesperidin, naringin can be 1: 1 to 9: 1.
3, the preparation method of claim 1 or 2 described Fructus Aurantii Immaturuss or Fructus Aurantii effective site, it comprises extracts merge extractive liquid, with Chinese medicine Fructus Aurantii Immaturus or Fructus Aurantii with ethanol, reclaims ethanol to there not being the alcohol flavor, obtains the effective site of Fructus Aurantii Immaturus or Fructus Aurantii.
4, claim 1 or 2 described Fructus Aurantii Immaturuss or Fructus Aurantii effective site are being used to prepare the purposes that gastric motilitys such as treating flatulence, anorexia, dyspepsia lacks the medicine of property diseases.
5, claim 1 or 2 described Fructus Aurantii Immaturuss or Fructus Aurantii effective site are in the purposes of the medicine that is used to prepare respiratory tract infection diseases such as treatment tracheitis, cough.
6, contain the compositions of claim 1 or 2 described Fructus Aurantii Immaturuss or Fructus Aurantii effective site, it comprises the described Fructus Aurantii Immaturus of claim 1 or Fructus Aurantii effective site and/or pharmaceutic adjuvant.
7, compositions according to claim 6, it is tablet, granule, pill, capsule, effervescent tablet, syrup, paste nourishing agent, soft capsule, Emulsion, powder, slow releasing agent, controlled release agent, targeting preparation or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410070123 CN1733125B (en) | 2004-08-02 | 2004-08-02 | Pharmaceutical purpose of effective parts of immature Bitter orange or trifoliate-orange root-bark |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410070123 CN1733125B (en) | 2004-08-02 | 2004-08-02 | Pharmaceutical purpose of effective parts of immature Bitter orange or trifoliate-orange root-bark |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1733125A true CN1733125A (en) | 2006-02-15 |
| CN1733125B CN1733125B (en) | 2010-04-28 |
Family
ID=36075880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410070123 Active CN1733125B (en) | 2004-08-02 | 2004-08-02 | Pharmaceutical purpose of effective parts of immature Bitter orange or trifoliate-orange root-bark |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1733125B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100210573A1 (en) * | 2008-12-18 | 2010-08-19 | Citrox Limited | Compound and compositions for treatment of disease |
| CN101152202B (en) * | 2007-09-29 | 2010-11-24 | 中国药科大学 | Pharmaceutical composition for treating apparatus respiratorius disease and method for preparing the same |
| CN102050855A (en) * | 2010-12-28 | 2011-05-11 | 陕西嘉禾植物化工有限责任公司 | Method for comprehensively extracting synephrine and hesperidine from immature bitter orange raw material |
| CN102416062A (en) * | 2010-12-06 | 2012-04-18 | 成都中医药大学 | New application of immature bitter orange or immature bitter orange extract |
| CN102935131A (en) * | 2011-08-15 | 2013-02-20 | 天津药物研究院 | Application of Fructus Aurantii Immaturus total flavonoid extract in preparation of drug treating bronchial asthma |
| CN104189346A (en) * | 2014-09-09 | 2014-12-10 | 辽宁华润本溪三药有限公司 | New pharmaceutical composition capable of promoting gastrointestinal motility and preparation method thereof |
| CN105902556A (en) * | 2016-04-22 | 2016-08-31 | 江西中医药大学 | Combination medicine based on active components in Fructus Aurantii, and use thereof |
| WO2021151259A1 (en) * | 2020-01-31 | 2021-08-05 | 中山大学 | Use of 3-(4-hydroxyphenyl)propionic acid in preparation of drugs for preventing and treating respiratory tract infection |
| CN114470052A (en) * | 2022-02-18 | 2022-05-13 | 江西农业大学 | Application of traditional Chinese medicine immature bitter orange ethanol extract in preparation of antibacterial drugs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1235051A (en) * | 1999-04-13 | 1999-11-17 | 曾健国 | Puzhi defatting health-care products |
-
2004
- 2004-08-02 CN CN 200410070123 patent/CN1733125B/en active Active
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152202B (en) * | 2007-09-29 | 2010-11-24 | 中国药科大学 | Pharmaceutical composition for treating apparatus respiratorius disease and method for preparing the same |
| US20100210573A1 (en) * | 2008-12-18 | 2010-08-19 | Citrox Limited | Compound and compositions for treatment of disease |
| CN102416062A (en) * | 2010-12-06 | 2012-04-18 | 成都中医药大学 | New application of immature bitter orange or immature bitter orange extract |
| CN102416062B (en) * | 2010-12-06 | 2014-02-26 | 成都中医药大学 | New application of immature bitter orange or immature bitter orange extract |
| CN102050855A (en) * | 2010-12-28 | 2011-05-11 | 陕西嘉禾植物化工有限责任公司 | Method for comprehensively extracting synephrine and hesperidine from immature bitter orange raw material |
| CN102935131A (en) * | 2011-08-15 | 2013-02-20 | 天津药物研究院 | Application of Fructus Aurantii Immaturus total flavonoid extract in preparation of drug treating bronchial asthma |
| CN104189346A (en) * | 2014-09-09 | 2014-12-10 | 辽宁华润本溪三药有限公司 | New pharmaceutical composition capable of promoting gastrointestinal motility and preparation method thereof |
| CN104189346B (en) * | 2014-09-09 | 2016-07-06 | 辽宁华润本溪三药有限公司 | A kind of pharmaceutical composition of short digestive tract power and preparation method thereof |
| CN105902556A (en) * | 2016-04-22 | 2016-08-31 | 江西中医药大学 | Combination medicine based on active components in Fructus Aurantii, and use thereof |
| WO2021151259A1 (en) * | 2020-01-31 | 2021-08-05 | 中山大学 | Use of 3-(4-hydroxyphenyl)propionic acid in preparation of drugs for preventing and treating respiratory tract infection |
| CN114470052A (en) * | 2022-02-18 | 2022-05-13 | 江西农业大学 | Application of traditional Chinese medicine immature bitter orange ethanol extract in preparation of antibacterial drugs |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1733125B (en) | 2010-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10251927B2 (en) | Process to enhance the bioactivity of Ashwagandha extracts | |
| CN1742763A (en) | Use of Wucenglong extract in preparing health-care product and medicines | |
| CN1733125B (en) | Pharmaceutical purpose of effective parts of immature Bitter orange or trifoliate-orange root-bark | |
| CN1300176C (en) | New saponin and its derivative, its preparation method and its use in medicine | |
| CN104815138A (en) | Immature bitter orange extract, preparation and application | |
| CN108815218B (en) | Pharmaceutical composition and use thereof | |
| CN102342945B (en) | Application of Cortex Ilicis Rotundae saponin compound in preparing anti-inflammatory and analgetic medicament | |
| CN1836665A (en) | Pharmaceutical uses of hesperidin or its composition | |
| CN1817898A (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| CN1286466C (en) | Chinese medicine preparation for treating rheumatism and preparation and use | |
| CN1733765A (en) | Purple bergenia element pentaacetylate and its uses | |
| CN1704065A (en) | Pharmaceutical use of hesperidin and/or naringin | |
| CN1724014A (en) | Extractive of total saponin of clematis root, prepn. method and pharmaceutical use thereof | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN1217669C (en) | Naringin used in preparing medicine for curing acute and chronic bronchitis | |
| CN103316103B (en) | Coccidian-expelling and dysentery-stopping mixture for livestock and preparation method thereof | |
| CN1064048C (en) | Five compounds of Qingyang ginseng glucoside and its preparation method and application | |
| CN103880913B (en) | A kind of compound and application thereof with hepatoprotective effect | |
| CN102861278B (en) | Lipid-lowering extract from effective parts of sharpleaf galangal fruit and preparation and application thereof | |
| CN1452967A (en) | Application of cepharanthine in preparing medicine for resisting SARS virus | |
| CN101721450B (en) | Application of oriental cocklebur root chloroform extract used for treating peritonitis | |
| CN1205939C (en) | Use of total polygalin in preparing medicine for promoting gastrointestinal peristalsis | |
| CN103923156B (en) | There is saponin compound and the application thereof of hepatoprotective effect | |
| CN1695649A (en) | Soft capsule of extractive from active ingredient of jingangteng, and preparation method | |
| CN1426783A (en) | Application of evodiamine in the preparation of medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: JIANGXI QINGFENG DRUGS RESEARCH CO., LTD. Free format text: FORMER NAME: JIANGXI TIANKE MEDICAL DEVELOPMENT CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 341000 East Road, Shahe Industrial Park, Jiangxi, Ganzhou, No. 8 Patentee after: Jiangxi Qingfeng Drugs Research Co., Ltd. Address before: 341000 Jiangxi province Zhanggong District of Ganzhou City, Shahe Industrial Zone Patentee before: Tianke Medical Development Co., Ltd., Jiangxi |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190116 Address after: 341000 East Avenue, Shahe Industrial Park Station, Zhanggong District, Ganzhou City, Jiangxi Province Patentee after: Jiangxi Qingfeng Pharmaceutical Co., Ltd. Address before: 341000 No. 8 East Avenue, Shahe Industrial Park Station, Ganzhou City, Jiangxi Province Patentee before: Jiangxi Qingfeng Drugs Research Co., Ltd. |